IPC Copenhagen

International PharmaScience Center (IPC), Copenhagen

Snapshot	State of the art purpose built R&D facilities based in Scandinavia’s leading biotech hub1 with overall responsibility for the coordination of all Ferring’s R&D work.
Location	Medicon Valley [url: "http://www.mediconvalley.com/" ], Copenhagen, Denmark.
R&D Focus	IPC conducts pharmaceutical development2 [url: "/en/randd/Creating+New+Medicines/Drug+Development/Product+Development.htm#pharmadev" ], non-clinical development3 , clinical development4 and regulatory affairs5 [url: "/en/randd/Creating+New+Medicines/Drug+Development/Regulatory+Affairs.htm" ].
Employees	IPC employs over 250 people, split between its different specialist areas. Pharmaceutical development and clinical development employ the largest number of people, followed by non-clinical development and regulatory affairs.
Speciality areas	IPC undertakes work on all Ferring therapy areas.
History	1999: Ferring’s International PharmaScience Center was established 2002: Ferring’s IPC moves into new purpose built state of the art facilities

Contact details

International PharmaScience Center
Kay Fiskers Plads 11
DK 2300
Copenhagen
Denmark

Phone: +45 88 16 88 17
Fax: +45 88 16 88 19

Glossary Entries
1) biotech hub - A specified geographical area where a significant number of biotechnology related organisations such as biotech companies, universities and research institutes are gathered. Biotech hubs often benefit from government investment e.g. infrastructure, financial incentives, government research institutes and practical assistance. Examples include Medicon Valley in Northern Denmark/Southern Sweden and BioAlps near Lake Geneva in Switzerland.
2) pharmaceutical development - The development of the pharmaceutical formulation of a compound in its primary package and/or delivery system with all the necessary CMC (chemistry, manufacturing and control) documentation. Pharmaceutical development stages include pre-formulation studies and non-clinical development using bio-analytical methods.
3) non-clinical development - The non-clinical phase of drug development involves non-clinical safety, clinical pharmacology & experimental medicine, bioanalytical chemistry and regulatory affairs. Non-clinical trials are performed by various independent commercial, academic and government laboratories providing critical information for determining the most effective way to treat patients, and establish safe dosage levels.
4) clinical development - The processes through which clinical studies are undertaken to ascertain and further develop the clinical properties of the compound.
5) regulatory affairs - The process by which a medicine is verified as being in conformity with relevant legislation concerning its quality, safety and efficacy.

Mail